Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead’s Price Reduction Strategy: A Serious Move, But Not A Long-Term Model For US

Executive Summary

“Authorized generics” for Gilead's leading hepatitis C brands stands out from prior, largely symbolic responses to the lower list prices. This is not a political move, but a business one. It is also the clearest demonstration yet of why pricing reforms are necessary if lower list prices are the policy goal.

You may also be interested in...



Louisiana Purchase: State Eager To Test “Netflix Model” For Rx Spending

A subscription payment model could be a solution for high-priced drugs, Louisiana thinks – and appears to have at least one manufacturer willing to participate. Will the Trump Administration agree?

Gilead Lowering HCV Drug List Prices With Authorized Generics

Approach has been endorsed by Express Scripts as more workable solution than trying to cut list prices for drugs already on the market.

Who's Promised What: A Guide To Pharma Drug Pricing Pledges

Have pharma companies responded sufficiently to President Trump's call for “massive” price reductions?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS124019

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel